China · Delayed Price · Currency is CNY Guanhao Biotech Statistics
Total Valuation
Guanhao Biotech has a market cap or net worth of CNY 4.55 billion. The enterprise value is 4.45 billion.
| Market Cap | 4.55B |
| Enterprise Value | 4.45B |
Important Dates
The next estimated earnings date is Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Guanhao Biotech has 265.16 million shares outstanding. The number of shares has decreased by -2.89% in one year.
| Current Share Class | 265.16M |
| Shares Outstanding | 265.16M |
| Shares Change (YoY) | -2.89% |
| Shares Change (QoQ) | +11.10% |
| Owned by Insiders (%) | 1.87% |
| Owned by Institutions (%) | 5.41% |
| Float | 199.79M |
Valuation Ratios
The trailing PE ratio is 173.53.
| PE Ratio | 173.53 |
| Forward PE | n/a |
| PS Ratio | 11.59 |
| PB Ratio | 9.23 |
| P/TBV Ratio | 9.14 |
| P/FCF Ratio | 253.09 |
| P/OCF Ratio | 65.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 69.12, with an EV/FCF ratio of 247.54.
| EV / Earnings | 169.32 |
| EV / Sales | 11.34 |
| EV / EBITDA | 69.12 |
| EV / EBIT | 115.08 |
| EV / FCF | 247.54 |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.97 |
| Quick Ratio | 1.25 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.87 |
| Debt / FCF | 6.68 |
| Interest Coverage | 11.46 |
Financial Efficiency
Return on equity (ROE) is 3.40% and return on invested capital (ROIC) is 4.64%.
| Return on Equity (ROE) | 3.40% |
| Return on Assets (ROA) | 3.21% |
| Return on Invested Capital (ROIC) | 4.64% |
| Return on Capital Employed (ROCE) | 6.22% |
| Weighted Average Cost of Capital (WACC) | 5.29% |
| Revenue Per Employee | 741,185 |
| Profits Per Employee | 49,621 |
| Employee Count | 530 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.07 |
Taxes
In the past 12 months, Guanhao Biotech has paid 12.43 million in taxes.
| Income Tax | 12.43M |
| Effective Tax Rate | 43.14% |
Stock Price Statistics
The stock price has increased by +38.28% in the last 52 weeks. The beta is 0.21, so Guanhao Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +38.28% |
| 50-Day Moving Average | 15.43 |
| 200-Day Moving Average | 15.47 |
| Relative Strength Index (RSI) | 58.31 |
| Average Volume (20 Days) | 16,799,128 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guanhao Biotech had revenue of CNY 392.83 million and earned 26.30 million in profits. Earnings per share was 0.10.
| Revenue | 392.83M |
| Gross Profit | 307.95M |
| Operating Income | 38.69M |
| Pretax Income | 28.80M |
| Net Income | 26.30M |
| EBITDA | 58.16M |
| EBIT | 38.69M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 141.43 million in cash and 120.20 million in debt, with a net cash position of 21.24 million or 0.08 per share.
| Cash & Cash Equivalents | 141.43M |
| Total Debt | 120.20M |
| Net Cash | 21.24M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 493.49M |
| Book Value Per Share | 2.16 |
| Working Capital | 148.43M |
Cash Flow
In the last 12 months, operating cash flow was 69.85 million and capital expenditures -51.86 million, giving a free cash flow of 17.99 million.
| Operating Cash Flow | 69.85M |
| Capital Expenditures | -51.86M |
| Free Cash Flow | 17.99M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 78.39%, with operating and profit margins of 9.85% and 6.69%.
| Gross Margin | 78.39% |
| Operating Margin | 9.85% |
| Pretax Margin | 7.33% |
| Profit Margin | 6.69% |
| EBITDA Margin | 14.80% |
| EBIT Margin | 9.85% |
| FCF Margin | 4.58% |
Dividends & Yields
Guanhao Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.64% |
| Buyback Yield | 2.89% |
| Shareholder Yield | 2.89% |
| Earnings Yield | 0.58% |
| FCF Yield | 0.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Apr 16, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Guanhao Biotech has an Altman Z-Score of 8.56 and a Piotroski F-Score of 6.
| Altman Z-Score | 8.56 |
| Piotroski F-Score | 6 |